Double staining for CD33 and CD64 indicated that blood samples from both AML M4 patients, the AML M4/M5 patient and two of the three CMML patients yielded ∼70% CD33+ CD64+ blasts (Table 1). This evidence concerns the gene FCGR1A and chronic myelomonocytic leukemia.